| Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection (NCT04863066) | Beijing 302 Hospital | 2021-05-01 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 (NCT04223804) | AbbVie | 2020-01-30 |
| Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention (NCT03870438) | ANRS, Emerging Infectious Diseases | 2019-12-14 |
| Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV (NCT03869944) | ANRS, Emerging Infectious Diseases | 2019-12-04 |
| Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets (NCT04006704) | Janssen Pharmaceutica N.V., Belgium | 2019-10-10 |
| A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa (NCT03060629) | Janssen Vaccines & Prevention B.V. | 2017-11-03 |
| A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care (NCT03227861) | Janssen Scientific Affairs, LLC | 2017-07-31 |
| Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults (NCT02840474) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-04-24 |
| Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients (NCT03279835) | Centre Hospitalier Universitaire de Nice | 2017-03-16 |
| Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets (NCT02993237) | Janssen Research & Development, LLC | 2017-01-23 |
| Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals (NCT03708289) | Universitair Ziekenhuis Brussel | 2016-09-01 |
| Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) (NCT02652260) | Merck Sharp & Dohme LLC | 2016-03-04 |
| HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction (NCT04956861) | University of Colorado, Boulder | 2015-12-17 |
| A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003) (NCT02217904) | Merck Sharp & Dohme LLC | 2015-09-17 |
| Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla (NCT02547844) | Hospital Universitari Vall d'Hebron Research Institute | 2015-09-01 |
| HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (NCT02513147) | Hospital Universitari Vall d'Hebron Research Institute | 2015-06-01 |
| Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (NCT02285114) | Gilead Sciences | 2015-01-20 |
| Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (NCT02275780) | Merck Sharp & Dohme LLC | 2014-12-01 |
| Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (NCT01968551) | Gilead Sciences | 2013-09-03 |
| Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent (NCT01771562) | ANRS, Emerging Infectious Diseases | 2013-04-01 |
| Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients (NCT01702090) | Janssen-Cilag Ltd. | 2012-02-01 |
| Korean Post-marketing Surveillance for Reyataz® (NCT01450605) | Bristol-Myers Squibb | 2011-12-01 |
| Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 (NCT01345630) | ViiV Healthcare | 2011-09-01 |
| Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients (NCT01274780) | Juan A. Arnaiz | 2011-05-01 |
| PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (NCT01192035) | University of Aarhus | 2011-05-01 |
| A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022 (NCT01254656) | Pfizer | 2011-02-01 |
| A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (NCT00799864) | Janssen Sciences Ireland UC | 2011-01-01 |
| Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation (NCT01168167) | Christoph Stephan | 2010-06-01 |
| TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (NCT00980538) | Janssen Sciences Ireland UC | 2009-12-09 |
| Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART (NCT01024842) | University of Oxford | 2009-12-01 |
| Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers (NCT00982579) | Medical Research Council | 2009-11-01 |
| Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers (NCT00981695) | Medical Research Council | 2009-11-01 |
| Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects (NCT01084343) | Mymetics Corporation | 2009-11-01 |
| Intrauterine Insemination In HIV-Discordant Couples (NCT01173276) | Boston Medical Center | 2009-09-01 |
| Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 (NCT00807443) | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 2009-09-01 |
| Genotypic Resistant HIV Strains in Taiwan (NCT00954863) | National Taiwan University Hospital | 2009-08-01 |
| A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1 (NCT00824369) | Pfizer | 2009-07-01 |
| Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection (NCT00850395) | ViiV Healthcare | 2009-07-01 |
| A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication (NCT00840762) | Ruth M. Rothstein CORE Center | 2009-03-01 |
| Treatment De-Intensification and Residual HIV-1 in Youth (NCT00867854) | University of North Carolina, Chapel Hill | 2009-02-01 |
| PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir (NCT00838760) | Tibotec Pharmaceuticals, Ireland | 2009-02-01 |
| A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1 (NCT00824421) | Pfizer | 2009-02-01 |
| TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation (NCT00812292) | Tibotec Pharmaceuticals, Ireland | 2009-01-01 |
| TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents (NCT00665847) | Tibotec Pharmaceuticals, Ireland | 2008-11-01 |
| ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial (NCT00772902) | Gilead Sciences | 2008-10-01 |
| TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA. (NCT00741741) | Tibotec Pharmaceuticals, Ireland | 2008-07-01 |
| TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NCT00543725) | Tibotec Pharmaceuticals, Ireland | 2008-06-01 |
| TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine. (NCT00540449) | Tibotec Pharmaceuticals, Ireland | 2008-05-01 |
| Phase 1 Safety Study of Two Experimental HIV Vaccines (NCT00479999) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-05-24 |
| Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions (NCT01140139) | Swedish Institute for Infectious Disease Control | 2006-09-01 |
| A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents (NCT00355524) | Tibotec Pharmaceuticals, Ireland | 2006-06-01 |
| An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216). (NCT00359021) | Tibotec Pharmaceuticals, Ireland | 2006-06-01 |
| Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada (NCT00324649) | Gilead Sciences | 2006-05-01 |
| Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial (NCT00337181) | U.S. Army Medical Research and Development Command | 2006-05-01 |
| Fuzeon Viral Decay Pilot Study (NCT00334022) | Canadian Immunodeficiency Research Collaborative | 2006-02-01 |
| A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061 (NCT00348673) | Pfizer | 2006-02-01 |
| Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. (NCT00298350) | Gilead Sciences | 2006-02-01 |
| A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium (NCT00309205) | International Partnership for Microbicides, Inc. | 2005-12-01 |
| A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort (NCT00268827) | AIDS Arms Inc. | 2005-12-01 |
| Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects (NCT00144833) | GlaxoSmithKline | 2005-03-01 |
| Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial (NCT01177059) | Janssen-Cilag Pty Ltd | 2004-12-06 |
| Retrovirus Epidemiology Donor Study-II (REDS-II) (NCT00097006) | National Heart, Lung, and Blood Institute (NHLBI) | 2004-09-01 |
| A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018) (NCT00849732) | Merck Sharp & Dohme LLC | 2003-06-01 |
| A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016) (NCT00849680) | Merck Sharp & Dohme LLC | 2003-04-01 |
| An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection (NCT00074997) | Janssen-Cilag Pty Ltd | 2002-12-01 |
| TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients (NCT00412646) | Tibotec Pharmaceuticals, Ireland | 2002-06-01 |
| Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India (NCT00341796) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2002-06-01 |
| Retrovirus Epidemiology Donor Study I (REDS I) (NCT00005278) | National Heart, Lung, and Blood Institute (NHLBI) | 1989-07-01 |
| The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs (NCT00354627) | Tibotec Pharmaceuticals, Ireland | |